

ASX: EIQ RELEASE

7 JULY, 2022

**PRESENTATION OF RESEARCH FINDINGS BEHIND
ECHO IQ ALGORITHM AS LATE BREAKING SCIENCE
AT EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS**

Highlights

- **Ground-breaking research related to Echo IQ's algorithm for aortic stenosis to be presented at world's leading cardiology conference**
- **Echo IQ incorporating cutting-edge research into its product suite**

Sydney, Australia: AI and Medical Technology company ECHOIQ Limited ("Echo IQ", the Company) (ASX:EIQ) announces that the research and findings underpinning the company's latest AI-algorithm have been accepted for presentation as late-breaking science at the world's foremost cardiology conference, the European Society of Cardiology (ESC) Congress, to be held in Barcelona, Spain, 26-28 August, 2022.

Professor Geoff Strange from the University Notre Dame, and also the Echo IQ Chief Strategy and Research Officer, will be presenting the research "AI-Enhanced Detection of Aortic Stenosis". This work has been a collaboration between Prof. Strange and Professor David Playford (University of Notre Dame and also Echo IQ's Chief Medical Advisor) and the Company's Technical Director Rakesh Patel, and Data Scientist Dr. Andrew Watts.

Acceptance as late-breaking science at globally significant scientific conferences is difficult to secure, and is testament to the level of innovation Echo IQ is bringing to the sector. Cardiovascular disease remains the world's leading cause of death and the commercial opportunities for companies that support enhanced diagnosis appear to be significant.

Echo IQ will be represented at the ESC Congress to progress engagement with leading corporates in the cardiac ultrasound, reporting and treatment sectors already well-advanced in some cases.

Executive Chair Andrew Grover said: *"Being accepted as a late-breaker at the ESC Congress is further evidence of the ground-breaking work we are bringing to the cardiology market. The work being shared is fundamental to the solution for which we are seeking FDA clearance, expected to be completed in early 2023."*

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer

philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair

Andrew.grover@echoiq.ai / investors@echoiq.ai / +61 (0)481 339 512

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.